COMMUNIQUÉS West-GlobeNewswire

Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA
11/10/2018
– Trial will utilize PyL imaging in order to target the patients most likely to benefit, advancing the Company’s theranostic approach to the treatment of prostate cancer – NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- [...]
Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA™ in the United States
11/10/2018
FDA-Approved for the Treatment of Complicated Intra-Abdominal Infections Provides Broad Spectrum of Coverage Against Gram-negative, Gram-positive, and Anaerobic Bacteria for a Range of Patients with Empiric and [...]
Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305
11/10/2018
G100 development to accelerate in follicular lymphoma and beyond CMB305 to be deprioritized to support focus on G100 Cash runway extended into 2021 Conference call at 2:00 pm Pacific today SEATTLE and SOUTH SAN [...]
Chimerix to Host Annual Investor Update on October 17, 2018
11/10/2018
DURHAM, N.C., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host the Company's annual [...]
NSS Labs Announces 2018 Breach Detection Systems Group Test Results
11/10/2018
Three Products Receive Recommended Rating; Two Products Miss at Least One Evasion AUSTIN, Texas, Oct. 11, 2018 (GLOBE NEWSWIRE) -- NSS Labs, Inc., a global leader and trusted source for independent, fact-based [...]
CFN Media Enhances its LA Studio for Exclusive Interviews and CFN Weekly Show
11/10/2018
Seattle, WA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”, “CannabisFN”), the leading agency and financial media network dedicated to the worldwide cannabis industry, today [...]
CV Sciences, Inc. to be a Featured Panelist at TheStreet’s Investing Event on October 13th in New York, NY
11/10/2018
LAS VEGAS, Oct. 11, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc . (OTCQB:CVSI) (the “Company,” “CV Sciences,” “our,” “us” or “we”), preeminent supplier and manufacturer of phytocannabinoids including industry-leading [...]
Eckert & Ziegler BEBIG SA and Eckert & Ziegler Strahlen- und Medizintechnik AG will propose to their shareholders the merger of the two companies
11/10/2018
Press release Inside and regulated information 11 October 2018, 19:30 (CEST) Eckert & Ziegler BEBIG SA and Eckert & Ziegler Strahlen- und Medizintechnik AG will propose to their shareholders the merger of the [...]
Eckert & Ziegler BEBIG SA et Eckert & Ziegler Strahlen- und Medizintechnik AG vont proposer à leurs actionnaires la fusion entre les deux sociétés
11/10/2018
Communiqué de presse Information privilégiée et réglementée 11 Octobre 2018, 19:30 (CEST) Eckert & Ziegler BEBIG SA et Eckert & Ziegler Strahlen- und Medizintechnik AG vont proposer à leurs actionnaires la [...]
Texas Companies and Universities Bring World’s Largest Algae Technology Conference to The Woodlands
11/10/2018
Event showcases breakthrough algae innovations in human health, agriculture, wastewater and fuel HOUSTON, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Texas-based companies and universities are working with the Algae Biomass [...]
CTD Holdings to Host Webinar on its Phase I Clinical Trial for Niemann-Pick Disease Type C
11/10/2018
ALACHUA, Fla., Oct. 11, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced a one- [...]
Pediapharm Announces Closing of Subscription Receipt Offering for Total Gross Proceeds of $62 Million
11/10/2018
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Oct. 11, [...]
Virbac : revenue grew by +5.5% at constant exchange rates at the end of September 2018
11/10/2018
Revenue grew by +5.5% at constant exchange rates at the end of September 2018 KEY FIGURES Revenue Year-to-date September 2018 €634.3 million Total growth +0.7% Growth at constant exchange rates +5.5% Growth at constant [...]
Virbac : chiffre d'affaires en croissance de +5,5% à taux de change constants à fin septembre 2018
11/10/2018
Chiffre d'affaires en croissance de +5,5% à taux de change constants à fin septembre 2018 CHIFFRES CLÉS Chiffre d'affaires Neuf mois 2018 634,3 m€ Évolution globale +0,7% Croissance à taux de change constants +5,5% [...]
TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the 34th Congress of ECTRIMS
11/10/2018
Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial ECTRIMS data review conference call to be held today, October 11, 2018, 19:30 CEST/1:30pm ET NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- [...]
Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum
11/10/2018
DEVON, Pa., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric [...]
Corporate Update To Shareholders: Preparatory Work For Regulatory Filings On Track
11/10/2018
HASBROUCK HEIGHTS, N.J., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Following many shareholder enquiries in recent weeks Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide shareholders with a brief update on [...]
OncBioMune Advancing ProscaVax Towards Second Phase 2 Clinical Trial for Prostate Cancer with Protocol Submission to FDA
11/10/2018
BATON ROUGE, La., Oct. 11, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary [...]
Vital Therapies Provides Strategic Update
11/10/2018
SAN DIEGO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced [...]

Pages